ORGS · Orgenesis Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $347.0K | $246.0K | $141.0K | - | $110.0K | $6.97M | $7.21M | - | $7.99M |
| Cost of Revenue | - | $585.0K | $538.0K | $492.0K | - | $139.0K | $3.23M | $2.72M | - | $4.67M |
| Gross Profit | - | ($238.0K) | ($292.0K) | ($351.0K) | - | $7.00M | $6.14M | $4.32M | - | $3.32M |
| R&D | - | $4.52M | $1.49M | $2.37M | - | $808.0K | $7.84M | $3.28M | - | - |
| SG&A | - | $2.66M | $2.06M | $6.06M | - | $1.25M | $3.34M | $4.04M | - | $3.10M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | $538.0K | $706.0K | $381.0K | - | $191.0K | $501.0K | $578.0K | - | - |
| Operating Income | - | ($8.39M) | ($4.25M) | ($8.93M) | - | ($11.75M) | ($3.33M) | ($3.21M) | - | ($7.0K) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | $32.0K | $5.0K | $16.0K | - | $394.0K | $91.0K | $129.0K | - | $25.0K |
| Net Income | - | ($9.12M) | ($8.90M) | ($9.77M) | - | ($12.65M) | ($4.13M) | ($4.19M) | - | ($1.36M) |
| EPS - Basic | - | $1.93 | $2.30 | $2.90 | - | $4.30 | $1.50 | $1.60 | - | $0.50 |
| EPS - Diluted | - | $1.93 | $2.30 | $2.90 | - | $0.50 | $1.50 | $8.70 | - | - |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78.0K | $204.0K | $77.0K | $80.0K | $837.0K | $55.0K | $180.0K | $2.67M | $5.31M | $3.02M |
| Accounts Receivable | $40.0K | $161.0K | $240.0K | $245.0K | $88.0K | $71.0K | $6.0K | $37.74M | $36.18M | $23.74M |
| Inventory | - | - | - | $34.0K | $34.0K | $34.0K | $34.0K | $128.0K | $120.0K | $95.0K |
| Accounts Payable | - | - | - | - | - | - | - | $4.39M | $4.43M | $4.54M |
| Current Assets | $761.0K | $2.52M | $2.35M | $1.96M | $4.08M | $8.78M | $9.29M | $49.45M | $46.32M | $31.86M |
| Total Assets | $1.35M | $29.69M | $30.58M | $30.92M | $14.55M | $45.30M | $54.77M | $93.27M | $90.93M | $70.69M |
| Current Liabilities | $26.92M | $36.05M | $31.70M | $29.03M | $16.41M | $14.30M | $12.71M | $13.94M | $15.91M | $34.17M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $38.88M | $53.62M | $46.37M | $58.47M | $35.53M | $32.90M | $30.80M | $33.96M | $31.65M | $40.44M |
| Stockholders' Equity | ($37.50M) | ($23.90M) | ($15.50M) | ($27.72M) | ($20.98M) | $12.40M | $23.96M | $27.67M | $27.56M | $30.21M |
| Retained Earnings | ($224.79M) | ($204.41M) | ($195.29M) | ($186.39M) | ($176.62M) | ($142.23M) | ($129.58M) | ($125.45M) | ($121.26M) | ($117.16M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($4.44M) | - | - | - | ($7.24M) | - | - |
| Investing Cash Flow | - | - | - | ($68.0K) | - | - | - | ($1.31M) | - | - |
| Financing Cash Flow | - | - | - | $3.61M | - | - | - | $5.91M | - | - |
| CapEx | - | - | - | $204.0K | - | - | - | $1.28M | - | - |
| Free Cash Flow | - | - | - | ($4.64M) | - | - | - | ($8.53M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | -68.6% | -118.7% | -248.9% | - | 6368.2% | 88.0% | 59.9% | - | 41.6% |
| Operating margin | - | -2419.0% | -1727.6% | -6333.3% | - | -10684.5% | -47.7% | -44.4% | - | -0.1% |
| EBITDA margin | - | -2264.0% | -1440.7% | -6063.1% | - | -10510.9% | -40.5% | -36.4% | - | - |
| Net margin | - | -2628.2% | -3619.5% | -6925.5% | - | -11502.7% | -59.2% | -58.1% | - | -17.0% |
| Free cash flow margin | - | - | - | -3294.3% | - | - | - | -118.2% | - | - |
| FCF / Net income | - | - | - | 0.48 | - | - | - | 2.04 | - | - |
| R&D / Revenue | - | 1303.5% | 605.3% | 1680.9% | - | 734.5% | 112.4% | 45.5% | - | - |
| SG&A / Revenue | - | 767.7% | 837.8% | 4295.0% | - | 1131.8% | 47.8% | 56.0% | - | 38.9% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -30.7% | -29.1% | -31.6% | - | -27.9% | -7.5% | -4.5% | - | -1.9% |
| Return on equity | - | 38.2% | 57.5% | 35.2% | - | -102.1% | -17.2% | -15.1% | - | -4.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.03 | 0.07 | 0.07 | 0.07 | 0.25 | 0.61 | 0.73 | 3.55 | 2.91 | 0.93 |
| Quick ratio | 0.03 | 0.07 | 0.07 | 0.07 | 0.25 | 0.61 | 0.73 | 3.54 | 2.90 | 0.93 |
| Cash ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.05 | 0.00 | 0.01 | 0.19 | 0.33 | 0.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.04 | -1.24 | -1.97 | -1.12 | -0.69 | 3.65 | 2.29 | 3.37 | 3.30 | 2.34 |
| Liabilities / Assets | 28.78 | 1.81 | 1.52 | 1.89 | 2.44 | 0.73 | 0.56 | 0.36 | 0.35 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.01 | 0.01 | 0.00 | - | 0.00 | 0.13 | 0.08 | - | 0.11 |
| Inventory turnover | - | - | - | 14.47 | - | 4.09 | 95.06 | 21.27 | - | 49.12 |
| Days sales outstanding | - | 169d | 356d | 634d | - | 236d | 0d | 1910d | - | 1085d |
| Days inventory outstanding | - | - | - | 25d | - | 89d | 4d | 17d | - | 7d |
| Days payable outstanding | - | - | - | - | - | - | - | 588d | - | 355d |
| Cash conversion cycle | - | - | - | - | - | - | - | 1339d | - | 737d |
| Valuation | ||||||||||
| P / E | - | 2.3x | 2.6x | 2.8x | - | 12.4x | 9.3x | 1.4x | - | - |
| P / B | - | - | - | - | - | 14.6x | 16.4x | - | - | - |
| P / S | - | 60.6x | 947.8x | 1929.4x | - | 1643.7x | 56.5x | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 215.5% | -96.5% | -98.0% | - | -98.6% | -3.1% | 0.0% | - | -7.9% |
| Revenue CAGR (3y) | - | -65.8% | -71.4% | -75.3% | - | -60.1% | 58.6% | 56.6% | - | -4.3% |
| Revenue CAGR (5y) | - | -48.0% | -49.9% | -54.6% | - | -55.4% | 11.8% | 22.3% | - | 25.5% |
| Gross profit growth (YoY) | - | - | - | - | - | 110.9% | - | -33.5% | - | - |
| Operating income growth (YoY) | - | 28.6% | -27.7% | -178.6% | - | -167800.0% | 29.6% | 1.0% | - | - |
| Net income growth (YoY) | - | 27.9% | -115.7% | -133.1% | - | -833.1% | 24.0% | -4.5% | - | - |
| EPS growth (YoY) | - | 286.0% | 53.3% | -66.7% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | 65.7% | 16.4% | 27.2% | - | - |
| EPS CAGR (5y) | - | 34.4% | - | - | - | 7.4% | - | - | - | - |
| FCF growth (YoY) | - | - | - | 45.5% | - | - | - | -130.8% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -78.7% | - | - | - | - | -59.0% | -24.5% | -20.3% | -28.4% | -29.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$1.03M totalOctomera$533.0K · 51.5%
Therapies$525.0K · 50.7%
Eliminations($23.0K) · -2.2%
Product / service
$1.39M totalCell Process Development Services And Hospital Services$1.02M · 73.3%
Grant$356.0K · 25.6%
License Fees$15.0K · 1.1%
Geographic
$492.0K totalUS$492.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Orgenesis Inc. against the 5 most active filers in the same SIC group.